Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the manufacturer of pomalidomide (POM; Imnovid(®), Celgene) to submit evidence regarding the clinical and cost effectiveness of the drug in combination with dex...

Descripción completa

Detalles Bibliográficos
Autores principales: Büyükkaramikli, Nasuh C., de Groot, Saskia, Fayter, Debra, Wolff, Robert, Armstrong, Nigel, Stirk, Lisa, Worthy, Gill, Albuquerque de Almeida, Fernando, Kleijnen, Jos, Al, Maiwenn J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805808/
https://www.ncbi.nlm.nih.gov/pubmed/29086363
http://dx.doi.org/10.1007/s40273-017-0581-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805808/
https://www.ncbi.nlm.nih.gov/pubmed/29086363
http://dx.doi.org/10.1007/s40273-017-0581-6

Ejemplares similares